AMA Board of Trustees Strengthens its Position on Misapplication of CDC Guidelines

AMA_Logo_img
Share the News
  • 33
  •  
  •  
  • 5
  •  
    38
    Shares

This Tweeted report came from @ChadDKollas on June 10, 2019 as follows:

Board recommendations were adopted June 10, 2019 as follows:

1. That our American Medical Association (AMA) support balanced opioid-sparing policies that are not based on hard thresholds, but on patient individuality, and help ensure safe prescribing practices, minimize workflow disruption, and ensure patients have access to their medications  in a timely manner, without additional, cumbersome documentation requirements. (New HOD Policy)

2. That our AMA oppose the use of “high prescriber” lists used by national pharmacy chains, pharmacy benefit management companies or health insurance companies when those lists do not provide due process and are used to blacklist physicians from writing prescriptions for controlled substances and preventing patients from having the prescription filled at their pharmacy of choice. (New HOD Policy)

3. That our AMA reaffirm Policy D-120.932 (formerly Resolution 235-1-18). “Inappropriate Use of CDC Guidelines for Prescribing Opioids”.

4. That our AMA incorporate into their advocacy that clinical practice guidelines specific to cancer treatment, palliative care and end-of-life be utilized in lieu of CDC’s Guideline for Prescribing Opioids for Chronic Pain as per CDC’s clarifying recommendation.

  •  
  •  
  •  
  •  
  •  

1 thought on “AMA Board of Trustees Strengthens its Position on Misapplication of CDC Guidelines

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.